My ePortfolio Register   

Liquid biopsies to track clonal evolution and resistance in mCRC

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.07.16
Views: 1265

Dr Alberto Bardelli - Candiolo Cancer Institute, Turin, Italy

Dr Bardelli meets with ecancertv at WIN 2016 to discuss the impact of liquid biopsy sampling on colorectal cancer treatment selection.

By tracking the clonal evolution of tumours, he reports successes of genomic targeting for patients with HER2, TRK and ALK mutations, among others, and how samples can closely predict patient response, resistance and relapse.

Dr Bardelli considers the evolutionary niche of cancer, and patient wellbeing outcomes as a result of liquid biopsy compared to solid tissue sampling.

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence